Moderna (MRNA.US) announced today that it has begun a phase 2/3 clinical trial designed to position its COVID-19 vaccine for use in children aged 12 to less than 18 before the start of the 2021-22 school year. The drugmaker has dosed the first participant in a study expected to enroll 3,000 healthy people. The study is being conducted in collaboration with the Biomedical Advanced Research and Development Authority (BARDA). "Our goal is to generate data in the spring of 2021 that will support the use of mRNA-1273 in adolescents in advance of the 2021 school year," said Chief Executive Officer Stéphane Bancel. Meanwhile US FDA will meet on December 17th to discuss whether to recommend the use of Moderna's vaccine.
Yesterday Moderna received a downgrade from Needham from ‘Buy’ to ‘Hold’ rating. Analysts believe that Moderna's stock is fully valued after capturing an eightfold gain this year.
![]()
Moderna (MRNA.US) stock is testing major support at $150.00 which coincides with 50 SMA (green line) and upward trendline. As long as the price sits above it, the continuation of a upward trend looks probable. The nearest key resistance lies at the $178.68 level. However if sellers will manage to break below the support zone, a downward impulse towards $129.12 could be launched. Source: xStation5
This content has been created by XTB S.A. This service is provided by XTB S.A., with its registered office in Warsaw, at Prosta 67, 00-838 Warsaw, Poland, entered in the register of entrepreneurs of the National Court Register (Krajowy Rejestr Sądowy) conducted by District Court for the Capital City of Warsaw, XII Commercial Division of the National Court Register under KRS number 0000217580, REGON number 015803782 and Tax Identification Number (NIP) 527-24-43-955, with the fully paid up share capital in the amount of PLN 5.869.181,75. XTB S.A. conducts brokerage activities on the basis of the license granted by Polish Securities and Exchange Commission on 8th November 2005 No. DDM-M-4021-57-1/2005 and is supervised by Polish Supervision Authority.
